Skip to main content
. 2022 Mar 24;14:17588359221085232. doi: 10.1177/17588359221085232

Figure 5.

Figure 5.

Kaplan–Meier analysis of pyrotinib in patients who benefited from lapatinib ⩾ 6.0 and < 6.0 months. LA: lapatinib PFS.